CA2369820A1 - Acides nucleiques codant pour des polypeptides chimeres cd40/cd40l, leurs procedes de production et leurs utilisations - Google Patents

Acides nucleiques codant pour des polypeptides chimeres cd40/cd40l, leurs procedes de production et leurs utilisations Download PDF

Info

Publication number
CA2369820A1
CA2369820A1 CA002369820A CA2369820A CA2369820A1 CA 2369820 A1 CA2369820 A1 CA 2369820A1 CA 002369820 A CA002369820 A CA 002369820A CA 2369820 A CA2369820 A CA 2369820A CA 2369820 A1 CA2369820 A1 CA 2369820A1
Authority
CA
Canada
Prior art keywords
cd40l
nucleic acid
cells
domain
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002369820A
Other languages
English (en)
Inventor
Frank Dicker
Thomas Friess
Gerd Maass
Ulrich Pessara
Werner Scheuer
Stefan Seeber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99107611A external-priority patent/EP1067194A1/fr
Application filed by Individual filed Critical Individual
Publication of CA2369820A1 publication Critical patent/CA2369820A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne un acide nucléique codant pour un polypeptide chimère comprenant des fragments d'acide nucléique codant pour: i) un peptide signal mammifère et ce qui en découle; ii) le domaine de liaison et de trimérisation de CD40L et ce qui en découle; iii) un espaceur de 50 à 100 acides aminés et ce qui en découle; iv) les domaines transmembranaires et de transduction de signal de CD40. Cet acide nucléique est utile comme agent de thérapie génique pour le traitement local des tumeurs solides.
CA002369820A 1999-04-16 2000-04-13 Acides nucleiques codant pour des polypeptides chimeres cd40/cd40l, leurs procedes de production et leurs utilisations Abandoned CA2369820A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP99107611A EP1067194A1 (fr) 1999-04-16 1999-04-16 Vecteurs contenant des gènes codant pour CD40 et/ou CD40L, sous le contrôle du promoteur inductibles à cytokine, qui est un promoteur d'amyloide sérique à phase aigue humaine. Procédés de leur fabrication et leurs utilisations
EP99107611.8 1999-04-16
EP99113967.6 1999-07-17
EP99113967 1999-07-17
PCT/EP2000/003318 WO2000063395A1 (fr) 1999-04-16 2000-04-13 Acides nucleiques codant pour des polypeptides chimeres cd40/cd40l, leurs procedes de production et leurs utilisations

Publications (1)

Publication Number Publication Date
CA2369820A1 true CA2369820A1 (fr) 2000-10-26

Family

ID=26152970

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002369820A Abandoned CA2369820A1 (fr) 1999-04-16 2000-04-13 Acides nucleiques codant pour des polypeptides chimeres cd40/cd40l, leurs procedes de production et leurs utilisations

Country Status (8)

Country Link
EP (1) EP1173589A1 (fr)
JP (1) JP2003508016A (fr)
AR (1) AR023482A1 (fr)
AU (1) AU3966200A (fr)
CA (1) CA2369820A1 (fr)
IL (1) IL144952A0 (fr)
NO (1) NO20015003D0 (fr)
WO (1) WO2000063395A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2357051T3 (es) 2000-10-02 2011-04-15 Novartis Vaccines And Diagnostics, Inc. Anticuerpos humanos anti-cd40.
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
WO2005044855A2 (fr) 2003-11-04 2005-05-19 Chiron Corporation Utilisation d'anticorps monoclonaux antagonistes anti-cd40 pour le traitement de myelome multiple
CA2544852A1 (fr) 2003-11-04 2005-05-19 Chiron Corporation Procedes therapeutiques de tumeurs solides exprimant l'antigene de surface cellulaire cd40
PT1682177E (pt) 2003-11-04 2010-11-29 Xoma Technology Lt Utilização de anticorpos antagonistas anti-cd40 para o tratamento da leucemia linfocítica crónica
CA2544368C (fr) 2003-11-04 2014-04-01 Chiron Corporation Procedes de therapie pour des cancers lies a la cellule b
PT1682178E (pt) 2003-11-04 2010-10-21 Novartis Vaccines & Diagnostic Métodos de terapêutica para cancros que expressam o antigénio cd40
PL1889065T3 (pl) 2005-05-18 2013-12-31 Novartis Ag Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
WO2007124299A2 (fr) 2006-04-21 2007-11-01 Novartis Ag Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste
ES2520026T3 (es) 2006-09-18 2014-11-11 The Board Of Trustees Of The University Of Arkansas Composiciones y métodos para potenciar respuestas inmunitarias
BRPI0818736A2 (pt) 2007-10-30 2017-06-13 Univ Arkansas composições e métodos para intensificar imunorrepostas à bactéria flagelada
ES2599905T3 (es) 2007-11-01 2017-02-06 The Board Of Trustees Of The University Of Arkansas Composiciones y métodos para aumentar las respuestas inmunitarias a Eimeria
JP5568807B2 (ja) * 2008-06-06 2014-08-13 静岡県 プロテオミクス解析を用いたメラノーママーカーの同定
NO2525817T3 (fr) 2010-01-21 2018-01-06
PT2579901T (pt) 2010-06-09 2019-11-05 Univ Arkansas Vacina e métodos para reduzir infeção por campylobacter
WO2012075111A1 (fr) 2010-11-30 2012-06-07 Novartis Ag Utilisation d'anticorps anti-cd40 en thérapie combinée contre des cancers associés aux cellules b
EP2956165B1 (fr) 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Compositions et procédés pour renforcer des réponses immunitaires vis-à-vis d'eimeria ou limiter une infection par eimeria
EP3578190A1 (fr) 2013-03-15 2019-12-11 The Board of Trustees of the University of Arkansas Compositions et procédés pour améliorer les réactions immunitaires aux pathogènes entériques
MX2018013331A (es) 2016-05-03 2019-06-10 Univ Arkansas Vector de vacuna de levadura que incluye polipeptidos inmunoestimuladores y antigenicos y metodos para su uso.
CA3044424C (fr) 2016-11-21 2023-05-23 Nant Holdings Ip, Llc Traitement combine fractal
CA3098498A1 (fr) * 2018-06-14 2019-12-19 Nantbio, Inc. Proteines de fusion ligand-recepteur du type tnf et methodes associees
WO2020073045A1 (fr) * 2018-10-05 2020-04-09 Nantcell, Inc. Combo cd40 et cd40l dans un véhicule de vaccin à adénovirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
DE69233051T2 (de) * 1991-10-25 2004-03-11 Immunex Corp., Seattle Antikörper gegen CD40-L
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells

Also Published As

Publication number Publication date
NO20015003L (no) 2001-10-15
NO20015003D0 (no) 2001-10-15
JP2003508016A (ja) 2003-03-04
AU3966200A (en) 2000-11-02
IL144952A0 (en) 2002-06-30
WO2000063395A1 (fr) 2000-10-26
AR023482A1 (es) 2002-09-04
EP1173589A1 (fr) 2002-01-23

Similar Documents

Publication Publication Date Title
CA2369820A1 (fr) Acides nucleiques codant pour des polypeptides chimeres cd40/cd40l, leurs procedes de production et leurs utilisations
WO2002036769A2 (fr) Acides nucleiques codant des polypeptides chimeriques cd40/cd40l, procedes de production et utilisations de ces acides nucleiques
Wang et al. Antisense targeting of basic fibroblast growth factor and dibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth
EP0551401B2 (fr) Procedes et compositions pour la therapie et la potentialisation genetiques de l'immunite antitumorale
Hernández et al. Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene
Marr et al. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNFα
EP2145958B1 (fr) Nouveaux vecteurs d'expression contenant des gènes ligands de molécules accessoires et leurs utilisations pour l'immunomodulation et le traitement des tumeurs et des affections auto-immunes
ZA200107160B (en) Nucleic acids encoding CD40/CD40L chimeric polypeptides, methods for their production and uses thereof.
ZA200108175B (en) Immunotherapy of cancer through expression of truncated tumor-associated antigen.
KR100911624B1 (ko) Ｉｌ－１２ 및 ｉｌ－２３의 효율적인 공동발현 방법
Siemens et al. Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix
KR20210094535A (ko) 4-1bbl (cd137l) 및/또는 cd40l를 암호화하는 재조합 mva의 종양내 및/또는 정맥내 투여에 의한 암의 치료 방법
Liu et al. Systemic genetic transfer of p21WAF− 1 and GM-CSF utilizing of a novel oligopeptide-based EGF receptor targeting polyplex
US20240115606A1 (en) Cell-Based Therapeutics Targeting CD70
WO2002022175A2 (fr) Methode et composition de traitement des tumeurs par induction selective de l'apoptose
KR20200044000A (ko) 재조합 mva 및 항체의 정맥내 투여에 의한 암 치료를 위한 병용 요법
US20070105794A1 (en) Immunotherapy
US6900185B1 (en) Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
Marr et al. A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor α expressed from an adenovirus vector induces an antitumor response with reduced toxicity
KR20180102108A (ko) 재조합 CXADR 발현을 위한 조성물 및 방법 (Compositions And Methods For Recombinant CXADR Expression)
KR20030092003A (ko) 인터페론 조절 인자-1／인간 에스트로겐 수용체 융합단백질 및 암을 치료하기 위한 그의 용도
Reed et al. Construction and characterization of a recombinant adenovirus directing expression of the MAGE‐1 tumor‐specific antigen
Ryschich et al. Effect of Flt3 ligand gene transfer in experimental pancreatic cancer
JP2002529068A (ja) Ｆａｓ−誘導アポトーシスを用いた腫瘍の治療方法
WO2023205745A1 (fr) Cellules génétiquement modifiées, utilisations et procédés de fabrication y relatifs

Legal Events

Date Code Title Description
FZDE Discontinued